Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Ambrosia Biosciences Inc.
United States
- Boulder, CO
- 21/08/2024
- Series A
- $16,000,000
Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
- Industry Biotechnology Research
- Website https://ambrosiabiosciences.com/
- LinkedIn https://www.linkedin.com/company/ambrosia-biosciences/
Related People
Nick TraggisFounder
United States -
Boulder, Colorado
I am a CEO, mentor, and dealmaker with diverse experience in biotech, optics/photonics, and other high-tech physical industries. With a career foundation of technical problem solving and leadership skills, I am able to communicate effectively across the boardroom, laboratory, and shop floor as needed.
CAREER HIGHLIGHTS
• Led or advised 7 M&A transactions with >$500M in deal value creation
• >20 technology licensing/IP transfer agreements completed
• >$130M in financing raised from equity, debt, and non-dilutive(government) sources.
• Led the design and construction of 4 U.S. based manufacturing facilities within the optics and medical device industries.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)